Immix Biopharma, Inc.
IMMX
Positions held
Your positionsIMMX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $770.17M | Enterprise value | $433.49M | Trailing P/E | — | Forward P/E | -10.96 |
| PEG | — | Price / book | 2.90 | Beta | 0.24 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -34.2% | ROA | -20.5% | Debt / equity | 0.00 |
| Current ratio | 25.13 | Free cash flow | -$25.39M | Analyst recommendation | strong_buy | Mean target | $24.30 |
| 52w high | $15.10 | 52w low | $2.31 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$11.6M | -$10.1M | -$10.7M | -$7.6M | -$6.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.5M | -$10.8M | -$10.9M | -$7.7M | -$6.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
2026-10-05 · Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
2026-09-30 · Immix Biopharma Closes $125 Million Stock Offering
2026-09-30 · Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
2026-09-29 · BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
2026-09-29 · Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
2026-09-29 · Immix Biopharma Prices $125 Million Stock Offering
2026-09-29 · Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
2026-09-15 · Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating
2026-08-11 · Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating
2026-08-04 · Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Price (daily)
Full chart · RSI · MACD · patterns